A Retrospective Analysis of Multi-Drug Resistant Tuberculosis among Presumptive Pulmonary Drug-Resistant Tuberculosis Patients in Andaman & Nicobar Islands

Authors

  • SP Burma Head of the Department, Department of Tuberculosis and chest Diseases, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, Andaman and Nicobar Islands.
  • Keerthivasan Gurumurthy Microbiologist- External Quality Assurance, State TB control Society, Port Blair, Andaman and Nicobar Islands.
  • Arjun Sivadas DOTS Plus Site Senior Medical Officer, State TB control Society, Port Blair, Andaman and Nicobar Islands.

Keywords:

MDR-TB, Andaman and Nicobar Islands, DR-TB, CBNAAT

Abstract

Introduction: Tuberculosis is a contagious bacterial infection affecting more than 10 million people worldwide. It is a major public health concern in India especially with the increasing numbers of drug-resistant cases of tuberculosis. Lack of early diagnosis, inadequate and inappropriate treatment are the major contributors to the development of drug resistance. PMDT strategy strives for early diagnosis and appropriate treatment of drug-resistant TB. This study was undertaken to estimate the rate of occurrence of MDR-TB among presumptive DR-TB patients in Andaman & Nicobar Islands.

Materials and Methods: A retrospective data based study for the calendar year 2018 was done by the state TB centre of the Union Territory of Andaman and Nicobar Islands. All patients with presumptive pulmonary DR-TB (as defined by the PMDT guidelines 2017) were included in the study. The drug resistance was confirmed by phenotypic and genotypic methods.

Result: The total number of presumptive DR-TB cases during the calendar year 2018 was 235. Forty eight of the cases were confirmed to be MDR-TB cases. Additional drug resistance to Second Line Injectable aminoglycosides (SLI) and Fluoroquinolones (FQ) was found in 2 and 6 of the cases respectively. Two cases of extreme drug resistant tuberculosis were also found (MDR+SLI+FQ resistance).

Conclusion: The best strategy for the control of drug resistant tuberculosis is prevention, which can only be achieved by timely diagnosis and early initiation of appropriate treatment of drug resistant TB cases as per drug susceptibility results, thereby preventing their further transmission.

References

Annual Reports: Central TB Division, TB India Report 2018. [cited 2019 Jul 5]. Available from: https://

tbcindia.gov.in/index1.php.

Guideline for PMDT in India 2017 : Central TB Division. [cited 2019 Jul 5]. Available from: https://tbcindia.gov.

in/index1.php.

Dhole T, Maurya A, Singh A et al. Changing Patterns and Trends of Multidrug-resistant Tuberculosis at Referral

Centre in Northern India: A 4-year Experience. Indian J Med Microbiol 2013; 31(1): 40-46.

Sk B, Gc A, Preeti P et al. Prevalence of MDR-TB among New and Previously Treated Patients of Pulmonary

Tuberculosis in DRTB Centre of Faridkot - A Retrospective Study. International Journal of Contemporary Medical

Research 2017;4(6): 1283-1286.

Bhatt G, Vyas S, Trivedil K. An Epidemiological Study of Multi drug resistant Tuberculosis Cases Registered under Revised National Tuberculosis Control Programme of Ahmedabad City. Indian J Tuberc 2012; 59(1): 18-27.

Shah A, Shah R, Dave P. Factors contributing to Development of Multidrug Resistant Tuberculosis. Natl

J Physiol Pharm Pharmacol 2018; 8(10): 1463-1469.

Gaude GS, Hattiholli J, Kumar P. Risk Factors and Drugresistance Patterns Among Pulmonary Tuberculosis

Patients in Northern Karnataka region, India. Niger Med J J Niger Med Assoc 2014; 55: 327-332.

Sharma SK, Kumar S, Saha PK et al. Prevalence of Multidrug-resistant Tuberculosis Among Category II

Pulmonary Tuberculosis Patients. Indian J Med Res 2011; 133: 312-315.

Shri Ram Ganesh RT, Manimaran Namasivayam K, Uma N et al. A Retrospective Study Risk Factor Analysis in

MDR TB Cases Among Rural Population of Thanjavur Medical College and Hospital, Thanjavur, Tamilnadu. J

Evid Based Med Healthc 2018; 5: 1211-1215.

Venkatesh U, Srivastava D, Srivastava A et al. Epidemiological Profile of Multidrug-resistant

Tuberculosis Patients in Gorakhpur Division, Uttar Pradesh, India. J Fam Med Prim Care 2018; 7(3): 589- 595.

Kumar A, Singh A, Upadhyay V et al. Epidemiology of Multi-drug-resistant tuberculosis in Northern India.

Biomed Biotechnol Res J BBRJ 2018; 2(2): 112-121.

Arinaminpathy N, Batra D, Khaparde S et al. The Number of Privately Treated Tuberculosis Cases in

India: An Estimation from Drug Sales Data. Lancet Infect Dis 2016; 16(11): 1255-1260.

Dalal A, Pawaskar A, Das M et al. Resistance Patterns Among Multidrug-resistant Tuberculosis Patients in

Greater Metropolitan Mumbai: Trends Over Time. PloS One 2015; 10(1): e0116798.

Satyanarayana S, Subbaraman R, Shete P et al. Quality of Tuberculosis Care in India: a Systematic Review. Int J

Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 2015; 19(7): 751-763.

Pothula M, Reddy S, Vasundhara P et al. Study of Prevalence of Multi-Drug Resistant Tuberculosis in a

Tertiary Care Hospital. BMC Infect Dis 2012; 12(Suppl 1): P29.

Downloads

Published

2019-10-11

Issue

Vol. 5 No. 2 (2019): Recent Advances in Pathology & Laboratory Medicine

Section

Research Article

License

 

We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________

Important

(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.

(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.

(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.